ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines
ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines |
|
https://doi.org/10.18632/oncotarget.28551
Mathew Lozinski,
Nikola A. Bowden,
Moira C. Graves,
Michael Fay,
Bryan W. Day,
Brett W. Stringer,
and Paul A. Tooney
|
| 1-18 |
Retraction: Decreased long intergenic noncoding RNA P7 predicts unfavorable prognosis and promotes tumor proliferation via the modulation of the STAT1-MAPK pathway in hepatocellular carcinoma
Retraction: Decreased long intergenic noncoding RNA P7 predicts unfavorable prognosis and promotes tumor proliferation via the modulation of the STAT1-MAPK pathway in hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.28366
Sijie Cheng,
Tieling Li,
Cheng Wang,
Keyu Wang,
Chengcai Lai,
Jin Yan,
Hongxia Fan,
Fang Sun,
Zhaohai Wang,
Peirui Zhang,
Linxiang Yu,
Zhixian Hong,
Guanglin Lei,
Baijun Sun,
Yuan Gao,
Zhaohui Xiao,
Xu Ji,
Ruilan Wang,
Jianzhong Wu,
Xiliang Wang,
Shaogeng Zhang,
and Penghui Yang
|
| 19-19 |
Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma
Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma |
|
https://doi.org/10.18632/oncotarget.28548
Bilal M. El-Masri,
Benedeta Leka,
Fatima Mustapha,
Michael Tveden Gundesen,
Maja Hinge,
Thomas Lund,
Thomas L. Andersen,
Marta Diaz-delCastillo,
and Abbas Jafari
|
| 20-26 |
Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report
Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report |
|
https://doi.org/10.18632/oncotarget.28550
Shreya Bhatia,
Manuel G. Cortez,
Spencer Lessans,
and Wade T. Iams
|
| 27-30 |
The fate of drug discovery in academia; dumping in the publication landfill?
The fate of drug discovery in academia; dumping in the publication landfill? |
|
https://doi.org/10.18632/oncotarget.28552
Uzma Saqib,
Isaac S. Demaree,
Alexander G. Obukhov,
Mirza S. Baig,
Amiram Ariel,
and Krishnan Hajela
|
| 31-34 |
Retraction: Interferon gamma peptidomimetic targeted to interstitial myofibroblasts attenuates renal fibrosis after unilateral ureteral obstruction in mice
Retraction: Interferon gamma peptidomimetic targeted to interstitial myofibroblasts attenuates renal fibrosis after unilateral ureteral obstruction in mice |
|
https://doi.org/10.18632/oncotarget.28532
Fariba Poosti,
Ruchi Bansal,
Saleh Yazdani,
Jai Prakash,
Leonie Beljaars,
Jacob van den Born,
Martin H. de Borst,
Harry van Goor,
Jan-Luuk Hillebrands,
and Klaas Poelstra
|
| 35-35 |
Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation
Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation |
|
https://doi.org/10.18632/oncotarget.28544
Mark Lee,
and Luc GT Morris
|
| 36-48 |
BCAS1 defines a heterogeneous cell population in diffuse gliomas
BCAS1 defines a heterogeneous cell population in diffuse gliomas |
|
https://doi.org/10.18632/oncotarget.28553
Raquel Morales-Gallel,
María José Ulloa-Navas,
Patricia García-Tárraga,
Ricardo Prat-Acín,
Gaspar Reynés,
Pedro Pérez-Borredá,
Luis Rubio,
Vivian Capilla-González,
Jaime Ferrer-Lozano,
and José Manuel García-Verdugo
|
| 49-64 |
Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma
Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma |
|
https://doi.org/10.18632/oncotarget.28547
Ashley Del Dosso,
Elizabeth Tadevosyan,
and James R. Berenson
|
| 65-75 |
Differential expression of Mad2 gene is consequential to the patterns of histone H3 post-translational modifications in its promoter region in human esophageal cancer samples
Differential expression of Mad2 gene is consequential to the patterns of histone H3 post-translational modifications in its promoter region in human esophageal cancer samples |
|
https://doi.org/10.18632/oncotarget.28554
Chongtham Sovachandra Singh,
Nabamita Boruah,
Atanu Banerjee,
Sillarine Kurkalang,
Pooja Swargiary,
Hughbert Dakhar,
and Anupam Chatterjee
|
| 76-89 |
Retraction: Long noncoding RNA TUG1 is a diagnostic factor in lung adenocarcinoma and suppresses apoptosis via epigenetic silencing of BAX
Retraction: Long noncoding RNA TUG1 is a diagnostic factor in lung adenocarcinoma and suppresses apoptosis via epigenetic silencing of BAX |
|
https://doi.org/10.18632/oncotarget.28462
Huan Liu,
Guizhi Zhou,
Xin Fu,
Haiyan Cui,
Guangrui Pu,
Yao Xiao,
Wei Sun,
Xinhua Dong,
Libin Zhang,
Sijia Cao,
Guiqin Li,
Xiaowei Wu,
and Xu Yang
|
| 90-90 |
Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis
Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis |
|
https://doi.org/10.18632/oncotarget.28512
P.A. Shatalov,
N.A. Falaleeva,
E.A. Bykova,
D.O. Korostin,
V.A. Belova,
A.A. Zabolotneva,
A.P. Shinkarkina,
A. Yu Gorbachev,
M.B. Potievskiy,
V.S. Surkova,
Zh V. Khailova,
N.A. Kulemin,
Denis Baranovskii,
A.A. Kostin,
A.D. Kaprin,
and P.V. Shegai
|
| 91-103 |
Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells |
|
https://doi.org/10.18632/oncotarget.28536
Yunfei Liao,
Lulu Chen,
Yong Feng,
Jacson Shen,
Yan Gao,
Gregory Cote,
Edwin Choy,
David Harmon,
Henry Mankin,
Francis Hornicek,
and Zhenfeng Duan
|
| 104-105 |
Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland
Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland |
|
https://doi.org/10.18632/oncotarget.28555
Wei Zhang,
Arndt A. Schmitz,
Roosa E. Kallionpää,
Merja Perälä,
Niina Pitkänen,
Mikko Tukiainen,
Erika Alanne,
Korinna Jöhrens,
Renate Schulze-Rath,
Bahman Farahmand,
and Jihong Zong
|
| 106-116 |
Combining causal and correlative approaches to discover biomarkers of response to paclitaxel
Combining causal and correlative approaches to discover biomarkers of response to paclitaxel |
|
https://doi.org/10.18632/oncotarget.28549
Alberto Moscona-Nissan,
Karl J. Habashy,
Victor A. Arrieta,
Adam M. Sonabend,
and Crismita Dmello
|
| 117-122 |
Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy
Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy |
|
https://doi.org/10.18632/oncotarget.28560
Changhwan Yoon,
Kevin K. Chang,
Jun Ho Lee,
William D. Tap,
Charles P. Hart,
M. Celeste Simon,
and Sam S. Yoon
|
| 123-123 |
GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells
GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells |
|
https://doi.org/10.18632/oncotarget.28557
Michael R. Booth,
Laurence Booth,
Jane L. Roberts,
Cameron West,
and Paul Dent
|
| 124-133 |
Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health
Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health |
|
https://doi.org/10.18632/oncotarget.28561
Elisabetta De Matteis,
Maria Rosaria Tumolo,
Paolo Tarantino,
Mariangela Ciccarese,
Tiziana Grassi,
Francesco Bagordo,
Maria Rita De Giorgio,
Emanuele Rizzo,
and Graziana Ronzino
|
| 134-141 |
Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer |
|
https://doi.org/10.18632/oncotarget.28523
Maryam Zanjirband,
Nicola Curtin,
Richard J. Edmondson,
and John Lunec
|
| 142-142 |
Correction: YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model
Correction: YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model |
|
https://doi.org/10.18632/oncotarget.28524
Tsion Zewdu Minas,
Jenny Han,
Tahereh Javaheri,
Sung-Hyeok Hong,
Michaela Schlederer,
Yasemin Saygideğer-Kont,
Haydar Çelik,
Kristina M. Mueller,
Idil Temel,
Metin Özdemirli,
Heinrich Kovar,
Hayriye Verda Erkizan,
Jeffrey Toretsky,
Lukas Kenner,
Richard Moriggl,
and Aykut Üren
|
| 143-143 |
Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas
Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas |
|
https://doi.org/10.18632/oncotarget.28559
Thomas M. Cardillo,
Maria B. Zalath,
Roberto Arrojo,
Robert M. Sharkey,
Serengulam V. Govindan,
Chien-Hsing Chang,
and David M. Goldenberg
|
| 144-158 |
GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells
GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells |
|
https://doi.org/10.18632/oncotarget.28558
Laurence Booth,
Jane L. Roberts,
Cameron West,
and Paul Dent
|
| 159-174 |
G-quadruplex landscape and its regulation revealed by a new antibody capture method
G-quadruplex landscape and its regulation revealed by a new antibody capture method |
|
https://doi.org/10.18632/oncotarget.28564
Subhamoy Datta,
Manthan Patel,
Chakkarai Sathyaseelan,
Chandrama Ghosh,
Akanksha Mudgal,
Divyesh Patel,
Thenmalarchelvi Rathinavelan,
and Umashankar Singh
|
| 175-198 |
Correction: Sigma-1 and Sigma-2 receptor ligands induce apoptosis and autophagy but have opposite effect on cell proliferation in uveal melanoma
Correction: Sigma-1 and Sigma-2 receptor ligands induce apoptosis and autophagy but have opposite effect on cell proliferation in uveal melanoma |
|
https://doi.org/10.18632/oncotarget.28519
Lucia Longhitano,
Carlo Castruccio Castracani,
Daniele Tibullo,
Roberto Avola,
Maria Viola,
Giuliano Russo,
Orazio Prezzavento,
Agostino Marrazzo,
Emanuele Amata,
Michele Reibaldi,
Antonio Longo,
Andrea Russo,
Nunziatina Laura Parrinello,
and Giovanni Li Volti
|
| 199-199 |
Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay
Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay |
|
https://doi.org/10.18632/oncotarget.28565
Josette Northcott,
Gabor Bartha,
Jason Harris,
Conan Li,
Fabio C.P. Navarro,
Rachel Marty Pyke,
Manqing Hong,
Qi Zhang,
Shuyuan Ma,
Tina X. Chen,
Janet Lai,
Nitin Udar,
Juan-Sebastian Saldivar,
Erin Ayash,
Joshua Anderson,
Jiang Li,
Tiange Cui,
Tu Le,
Ruthie Chow,
Randy Jerel Velasco,
Chris Mallo,
Rose Santiago,
Robert C. Bruce,
Laurie J. Goodman,
Yi Chen,
Dan Norton,
Richard O. Chen,
and John M. Lyle
|
| 200-218 |
Retraction: PDIA6 promotes the proliferation of HeLa cells through activating the Wnt/β-catenin signaling pathway
Retraction: PDIA6 promotes the proliferation of HeLa cells through activating the Wnt/β-catenin signaling pathway |
|
https://doi.org/10.18632/oncotarget.28522
Huijun Gao,
Bing Sun,
Hailu Fu,
Xinming Chi,
Faming Wang,
Xiaoyu Qi,
Jun Hu,
and Shujuan Shao
|
| 219-219 |
ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells
ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells |
|
https://doi.org/10.18632/oncotarget.28563
Benigno C. Valdez,
Bin Yuan,
David Murray,
Jeremy L. Ramdial,
Uday Popat,
Yago Nieto,
and Borje S. Andersson
|
| 220-231 |
From osimertinib to preemptive combinations
From osimertinib to preemptive combinations |
|
https://doi.org/10.18632/oncotarget.28569
Mikhail V. Blagosklonny
|
| 232-237 |
Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer
Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer |
|
https://doi.org/10.18632/oncotarget.28567
Haven R. Garber,
Sreyashi Basu,
Sonali Jindal,
Zhong He,
Khoi Chu,
Akshara Singareeka Raghavendra,
Clinton Yam,
Lumarie Santiago,
Beatriz E. Adrada,
Padmanee Sharma,
Elizabeth A. Mittendorf,
and Jennifer K. Litton
|
| 238-247 |
